Skip to main content

Table 1 Major cancer immunotherapeutics approved by the US Food and Drug Administration (FDA)

From: New opportunities for nanoparticles in cancer immunotherapy

Drug

(Trade Name)

Drug Type

(Target)

Targeted Cancer

FDA Approval

Date

Ipilimumab

(Yervoy®)

Monoclonal antibody

(CTLA-4)

Advanced melanoma

March 2011

Pembrolizumab

(Keytruda®)

Monoclonal antibody

(PD-1)

Advanced refractory melanoma and non–small cell lung cancer

September 2014

Nivolumab

(Opdivo®)

Monoclonal antibody

(PD-1)

Unresectable or metastatic melanoma squamous non–small cell lung cancer

December 2014

Atezolizumab

(Tecentriq®)

Monoclonal antibody

(PD-L1)

Locally advanced or metastatic bladder cancer

May 2016

Avelumab

(Bavencio®)

Monoclonal antibody

(PD-L1)

Locally advanced or metastatic bladder cancer

May 2017

Durvalumab

(Imfinzi®)

Monoclonal antibody

(PD-L1)

Locally advanced or metastatic bladder cancer

May 2017

  1. CTLA-4 cytotoxic T lymphocyte–associated protein-4, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1